Celularity Inc.: updates and filings

CELUNASDAQHealthcare · Pharmaceutical Preparations

Price

$0.57

November 17, 2026Market cap $19M

What Ploutos Investor adds for Celularity

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 51% since Oct 20, 2026, when the 10-Q these figures come from was filed ($1.26 then, $0.62 on Nov 16, 2026). The figures date from before that move.10-Q
  • A figure that did not match the numbers it is built from has been left out.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 13 daysAround Nov 30, 2026 · for Q3 2026

A rough estimate from when it has reported before, which has varied. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Apr 30, 2026 latest annualOct 20, 2026 latest quarterly
  • Nov 16, 2026Notice that the quarterly report will be filed late
    FormNT 10-Q
  • Nov 10, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Nov 10, 2026Additional annual meeting material
    FormDEFA14A
  • Nov 10, 2026Annual meeting proxy statement
    FormDEF 14A
  • Oct 29, 2026Other material events
    Form8-K
  • Oct 29, 2026Preliminary proxy statement
    FormPRE 14A
  • Oct 20, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Oct 20, 2026Annual report (amendment)for the period to Dec 31, 2025
    Form10-K/A
  • Sep 29, 2026Officer or director change
    Form8-K
  • Sep 29, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • Sep 28, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Sep 28, 2026Material agreement entered, new material financial obligation, unregistered sale of shares, officer or director change
    Form8-K
  • Sep 14, 2026Other material events
    Form8-K
  • Aug 14, 2026Notice that the quarterly report will be filed late
    FormNT 10-Q
  • Aug 7, 2026Officer or director change
    Form8-K
  • Jul 29, 2026Delisting notice
    Form8-K
  • Jul 22, 2026One of its securities removed from an exchange (usually a matured note)
    Form25-NSE
  • Jun 30, 2026Material agreement entered, new material financial obligation, officer or director change
    Form8-K
  • Jun 25, 2026Officer or director change
    Form8-K
  • Jun 23, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jun 12, 2026Delisting notice
    Form8-K
  • Jun 3, 2026Officer or director change, Regulation FD disclosure
    Form8-K
  • May 28, 2026Material agreement entered, new material financial obligation
    Form8-K
  • May 15, 2026Notice that the quarterly report will be filed late
    FormNT 10-Q
  • Apr 30, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 5, 2018.

The full analysis

What do Celularity's filings show?

The filings are where every one of Celularity's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.